CLCD
Tiene un S3 del 16 de junio para la venta "from time to time" de 150 millones de acciones.
Del trimestral de agosto:
The Company believes it has sufficient cash, cash equivalents and available for sale securities to enable it to complete its two Phase 3 pivotal clinical trials, and a portion of its long-term, open-label study of lasmiditan. The Company also estimates that such funds will support its operating expenses and capital expenditure requirements into mid-2017.
The Company has never been profitable and has incurred net losses in each year since inception. The Company’s net losses attributable to common stockholders were $38.5 million and $3.0 million for the years ended December 31, 2015 and 2014, respectively, and $16.3 million and $29.3 million for the three and six months ended June 30, 2016, respectively. As of June 30, 2016, the Company’s accumulated deficit was $116.4 million. These net losses resulted primarily from research and development programs, including preclinical development activities and clinical trials, and general and administrative costs associated with operations. The Company expects to continue to incur significant expenses and increasing operating losses for at least the next several years. These net losses and negative operating cash flows have had, and will continue to have, an adverse effect on stockholders’ equity and working capital. Because of the numerous risks and uncertainties associated with pharmaceutical product development, the Company is unable to accurately predict the timing or amount of increased expenses or when, or if, it will be able to achieve or maintain profitability.
He leído en Stocktwits que les quedan 40 kilos, lo cual, si es cierto, dado que acaban de finalizar la fase III, es nada para empezar el papeleo y la comercialización, y no olvidemos que con los resultados sería el momento idóneo para diluir.
Sin embargo, como no me fío de Stocktwits, agradecería que alguien le echara un vistazo a la contabilidad, desacargable directamente aquí: services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRndhUzUwWlc1cmQybDZZWEprTG1OdmJTOWtiM2R1Ykc5aFpDNXdhSEEvWVdOMGFXOXVQVkpVUmlacGNHRm5aVDB4TVRBNE16STRNaVp6ZFdKemFXUTlOVGM9JnR5cGU9MyZmbj1Db0x1Y2lkUGhhcm1hY2V1dGljYWxzSW5jLnJ0Zg==
Vamos, que estoy pensando en un buen corto. El riesgo es que con los buenos datos alguna BF quiera comprarla antes, pero como parece que estaba fuera de los radares, la opción dilución parece más plausible. Además el número de institucionales es bajo, sobre un 30%, así que deberían querer bajarla para subirse al carro.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
